Legal Guidance and Research / Experts / Reuben E. Jacob

Reuben E. Jacob

Reuben joined Maucher Jenkins as a partner in 2003 and Head of the Life Sciences and Medtech sector. He has built up a wealth of experience in advising clients operating in the fields of biotechnology, medtech, medical device patents and chemistry, including representing industrial clients, universities and research organisations. His special interest is in helping SMEs enhance their businesses by the creation of strategies for the acquisition, organisation and exploitation of their intellectual property rights. In terms of specialist technologies, Reuben has a particular interest in fungal genetics/technologies, medical device patents, medtech and laboratory instrumentation such as thermalcyclers and lab-on-a-chip devices. Over the years Reuben has gained considerable experience in conducting oppositions and appeals before the European Patent Office, including appearing at oral proceedings before the Examining Division, Opposition Divisions and Appeal Boards. He is experienced in intellectual property litigation, both in a support role in the UK and in the co-ordination of Europe-wide litigation strategies including enforcement and litigation support in Germany.

Practice Area

Panel

  • Q&A Panel

Qualified Year

  • 1996

Membership

  • Chartered Institute of Patent Attorneys (CIPA)
  • European Patent Institute (EPI)
  • FICPI and is a former FICPI UK Exco Delegate.
  • AIPPI and a regular Observer at the APAA World Congress.
  • The British Mycological Society and a Senior Associate Member of the Royal Society of Medicine.

Education

  • Honours degree in microbiology and genetics, University of London
  • Chartered Patent Attorney and European Patent Attorney

1 Contributions by Reuben E. Jacob

UK intellectual property for medical devices: confidentiality, patents, designs, trade marks, SPCs and parallel imports across the product lifecycle post-Brexit
PRACTICE NOTES
UK intellectual property for medical devices: confidentiality, patents, designs, trade marks, SPCs and parallel imports across the product lifecycle post-Brexit
Changes to intellectual property (IP) law from 1 January 2021 Before considering how IP law applies to medical devices, it is worth noting the position as at 31 December 2020 (IP completion day). The key development concerns EU trade marks (EUTMs) and registered Community designs (RCDs). From 1 January 2021, proprietors of EUTMs and RCDs that were already registered and published automatically acquired equivalent, registered and enforceable UK rights (UK comparable rights). Entries on the EUIPO register were effectively cloned onto the UKIPO register. These UK comparable rights were created automatically and at no charge to the rights holder. They preserve the filing date and, where relevant, the priority date of the original EUTM or RCD. They are independent of the EU rights and can be assigned or licensed on a standalone basis. Renewal fees must be paid separately for the original EUTMs and RCDs and for the UK comparable rights. The EU design regime has also been reformed. Regulation (EU) 2024/2822, which amends Regulation (EC) 6/2002, has applied...
Life Sciences
Expert page AD
If you expected to see yourself on this page, click here.